Here, we report the synthesis of a penta-selenopeptide consisting of five benzyl protected selenocysteine residues. This selenopeptide was well characterized by both one- and two-dimensional (D) NMR spectroscopies. We find that the solution conformation is enriched with β-sheet structures, which have a propensity to self-assemble and form amyloid fibrils.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/c8cc06528d | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SIRT2 and ALDH1A1 as critical enzymes for astrocytic GABA production in Alzheimer's disease.
Mol Neurodegener
January 2025
Center for Cognition and Sociality, Life Science Institute (LSI), Institute for Basic Science (IBS), Daejeon, Republic of Korea.
Background: Alzheimer's Disease (AD) is a neurodegenerative disease with drastically altered astrocytic metabolism. Astrocytic GABA and HO are associated with memory impairment in AD and synthesized through the Monoamine Oxidase B (MAOB)-mediated multi-step degradation of putrescine. However, the enzymes downstream to MAOB in this pathway remain unidentified.
View Article and Find Full Text PDFDeepDrug as an expert guided and AI driven drug repurposing methodology for selecting the lead combination of drugs for Alzheimer's disease.
Sci Rep
January 2025
Department of Electrical and Electronic Engineering, The University of Hong Kong, Hong Kong, China.
Alzheimer's Disease (AD) significantly aggravates human dignity and quality of life. While newly approved amyloid immunotherapy has been reported, effective AD drugs remain to be identified. Here, we propose a novel AI-driven drug-repurposing method, DeepDrug, to identify a lead combination of approved drugs to treat AD patients.
View Article and Find Full Text PDFCutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use.
J Prev Alzheimers Dis
January 2025
Clinical Memory Research Unit, Clinical Sciences in Malmö, Lund University, Lund, Sweden; Memory Clinic, Skåne University Hospital, Sweden. Electronic address:
As novel, anti-amyloid therapies have become more widely available, access to timely and accurate diagnosis has become integral to ensuring optimal treatment of patients with early-stage Alzheimer's disease (AD). Plasma biomarkers are a promising tool for identifying AD pathology; however, several technical and clinical factors need to be considered prior to their implementation in routine clinical use. Given the rapid pace of advancements in the field and the wide array of available biomarkers and tests, this review aims to summarize these considerations, evaluate available platforms, and discuss the steps needed to bring plasma biomarker testing to the clinic.
View Article and Find Full Text PDFIcariin improves learning and memory function by enhancing HRD1-mediated ubiquitination of amyloid precursor protein in APP/PS1 mice.
J Alzheimers Dis
January 2025
Key Laboratory of Basic Pharmacology of Guizhou Province, School of Pharmacy, Zunyi Medical University, Zunyi, China.
Background: One of the hallmark pathological characteristics of Alzheimer's disease (AD) is amyloid-β (Aβ) accumulated in brain, which is mainly derived from the proteolytic processing of amyloid-β protein precursor (AβPP). The ubiquitin-proteasome system is able to reduce Aβ generation by ubiquitination and degradation of AβPP. Icariin (ICA), a flavonoid isolated from Maxim.
View Article and Find Full Text PDFEthnic and racial influences on blood biomarkers for Alzheimer's disease: A systematic review.
J Alzheimers Dis
January 2025
Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Background: Little is known about confounding factors influencing Alzheimer's disease (AD) blood biomarker concentrations.
Objective: The objective of this systematic review was to explore the available evidence for the influences of ethnicity and race on AD blood biomarker concentrations.
Methods: We conducted a comprehensive systematic search in PubMed and Web of Science databases spanning from inception until 15 June 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!